Drug Trial Radar · NCT07820813
bNAbs and Anti-PD-1 in HIV
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Oct 7, 2026
Primary completion
Sep 15, 2029
Study completion Sep 15, 2030
Sponsor
- Lead sponsor
- Ole Schmeltz SøgaardAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aalborg University Hospital; Gødstrup Hospital; Odense University Hospital; Hvidovre University Hospital; Copenhagen University Hospital, Rigshospitalet; Oslo University Hospital; Karolinska University Hospital; Landspitali University Hospital
- First posted
- Sep 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Antiretroviral therapy (ART) has significantly extended the life expectancy of people living with HIV-1 (PLWH), but it does not cure the infection. Broadly neutralizing antibodies (bNAbs), such as 3BNC117 and 10-1074, not only neutralize circulating virus but also engage the immune system to enhance HIV-1-specific CD8+ T cell responses and stimulate autologous neutralizing antibody production. In some individuals who discontinue ART, bNAb treatment resulted in long-term post-treatment control. However, a major obstacle to immunotherapeutic strategies in PLWH is the immune dysfunction that persists despite long-term suppressive ART. One contributing factor is the immune checkpoint receptor programmed death-1 (PD-1), which is expressed on T cells and suppresses their function when engaged by its ligands. Blocking PD-1 with monoclonal antibodies (mAbs) can reverse T cell exhaustion, a strategy that has resulted in extraordinary increases in survival and cure in cancer treatment and in ex vivo and animal studies of HIV. These findings support the rationale for incorporating PD-1 inhibition in HIV cure strategies. Low-dose nivolumab, an anti-PD-1 mAb, has been shown to be safe in clinical trials. The hypothesis is that combining a single low-dose of nivolumab with long-acting bNAbs (3BNC117-LS and 10-1074-LS) during an analytical treatment interruption (ATI) will reduce T cell exhaustion and boost HIV-1-specific immune responses, as a novel strategy to induce sustained virological control without ART even after the bNAbs have been cleared from the body.
Conditions
- HIV-1
Interventions
3BNC117-LSDrug
bNAb; 30 mg/kg
10-1074-LSDrug
bNAb; 10 mg/kg
NivolumabDrug
Anti-PD-1a; low dose 1.0 mg/kg
PlaceboOther
Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from the day of stopping ART to the day of meeting criteria for loss of immunological control of HIV-1 (defined below)Time frame: 60 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aarhus University Hospital
Aarhus, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.